Qualifying Therapeutic Discovery Project Grants for the State of Michigan
The listings below represent the applicants that have been awarded a Qualifying Therapeutic Discovery Program Grant.
The project descriptions below were extracted from the applicant certification forms as submitted.
| Applicant Name | Project Name | Grants Awarded for 2009 | Grants Awarded for 2010 |
|---|---|---|---|
| Aastrom Biosciences, Inc. | A Phase III Stage Expanded, Autologous Stem Cell Product to Treat Severe CV Disease | $ 244,479.24 | |
| Accord Biomaterials Inc | Improved central venous and hemodialysis catheters to minimize infection and clotting | $ 211,615.81 | $ 32,863.44 |
| Accord Biomaterials, Inc. | Coronary stent with passivated surfaces to address restenosis and late-stage thrombosis | $ 178,815.24 | $ 65,664.01 |
| Accord Biomaterials, Inc. | Point-of-Care Diagnostic and Therapy Management Tool for Pulmonary Arterial Hypertension | $ 20,493.75 | $ 189,918.09 |
| Accuri Cytometers Inc | Development of the Accuri CS Clinical Flow Cytometry System | $ 244,479.25 | |
| Adeona Pharmaceuticals, Inc. | Estriol (Trimesta) | $ 35,493.50 | $ 208,985.75 |
| Adeona Pharmaceuticals, Inc. | Zinthionein and ZincMonoCysteine | $ 133,439.00 | $ 111,040.25 |
| AlphaCore Pharma, LLC | Treatment of Acute Coronary Syndromes with Recombinant LCAT Infusion | $ 244,479.25 | |
| Angott Medical Products, LLC | Multi-modality Breast Cancer Tester | $ 19,157.00 | $ 225,322.25 |
| ApoLife, Inc | Secretary IgA for orally applied therapy for treatment of Clostridium difficile infection. | $ 57,509.66 | $ 143,400.00 |
| Armune BioScience Inc | Molecular Diagnostics for Early Detection of Cancer | $ 244,479.24 | |
| Art Optical Contact Lens, Inc. | Therapeutic treatment of irregular corneas | $ 39,571.00 | $ 44,847.50 |
| AureoGen Bioscience Inc. | A novel antibiotic for the treatment of drug resistant bacterial infections | $ 136,897.60 | $ 107,581.64 |
| Aursos, Inc. | Aursos BB for primary & secondary osteoporosis and bone-building (anabolic) activity | $ 36,335.00 | $ 4,618.00 |
| Cardiavent Inc. | Development of CARD-024 for the treatment of hypertension and heart failure | $ 66,868.50 | $ 177,610.75 |
| Cayman Chemical Company Inc | EP4 Project | $ 172,016.50 | |
| Cayman Chemical Company Inc | H-PGDS Inhibition Project | $ 96,509.00 | $ 31,848.00 |
| Cayman Chemical Company, Inc | Tetranor Prostaglandin E Metabolite ELISA Project | $ 11,769.00 | $ 11,557.50 |
| Cerenis Therapeutics Inc | HDL-Mimetic Peptide/Phospholipid complex (CER-522) | $ 165,319.49 | $ 79,159.76 |
| Cerenis Therapeutics Inc. | CER-627 Low Flushing Niacin | $ 117,626.86 | $ 63,100.93 |
| Cerenis Therapeutics, Inc. | CER-002 | $ 43,428.26 | $ 95,307.06 |
| Compendia Bioscience, Inc. | Oncopredictor | $ 122,116.50 | $ 122,362.74 |
| CytoPherx, Inc | Selective CytoPheretic Device | $ 244,479.25 | |
| Delphinus Medical Technologies, inc. | Commercialization of SoftVue for early detection of Breast cancer | $ 238,705.00 | $ 5,774.25 |
| Esperion Therapeutics, Inc | ETC-1002 | $ 244,479.24 | |
| Genetics Squared, Inc. | Commercialization of a Stage I and II colorectal Cancer Recurrence Prognostic Technology | $ 244,479.24 | |
| Great Lakes BioSciences | Noninvasive cortical stimulation treatment of pain in fibromyalgia | $ 118,246.00 | $ 126,233.25 |
| Housey Pharmaceutical Research Laboratories, LLC | Novel Inhibitors for the Treatment of Highly Drug-Resistant Chronic Myelogenous Leukemia | $ 62,210.50 | $ 182,268.75 |
| HOUSEY PHARMACEUTICAL RESEARCH LABORATORIES, LLC | DISCOVERY AND DEVELOPMENT OF ANTI DIABETIC DRUGS | $ 201,356.00 | $ 43,123.25 |
| Hygieia Inc | PRIVATE-DOC | $ 80,761.72 | $ 163,717.53 |
| Innovative BioTherapies, Inc | Bioengineered Cellular/ Biomimetic-based Therapeutic System for treatment of SIRS | $ 244,479.24 | |
| Integrated Sensing Systems | Wireless Pressure Monitoring Implant for Tailored Medication of Cardiovascular Diseases | $ 244,479.24 | |
| Integrated Sensing Systems | A Microfluidic-Based Therapeutic Drug Infusion System | $ 244,479.25 | |
| IPGDx LLC | Determining an infectious process prior to syndromic findings as a biosurveillance tool | $ 244,479.25 | |
| IPGDx, LLC | Detection of Disease Severity & Progression, Treatment Effectiveness & Survival in Cancer | $ 244,479.24 | |
| Life Magnetics, Inc | Sensitive, Rapid Diagnostic device for Antibiotic Susceptibility Testing | $ 162,127.08 | |
| LPIT SOLUTIONS, INC | TRACKCORE SOFTWARE FOR OR IMPLANT MANAGEMENT | $ 210,295.33 | $ 34,183.92 |
| LVAD Technology Inc. | Via-Derm-2, a novel long-term percutaneous access device | $ 85,079.32 | $ 159,399.93 |
| Lycera Corp | ATPase Oral Therapeutic | $ 244,479.24 | |
| Lycera Corp. | RoR Gamma Therapeutic | $ 244,479.24 | |
| Meditrina Pharmaceuticals Inc. | MPI-676 | $ 12,860.00 | $ 99,477.63 |
| Metabolic Solutions Development Company | Novel Insulin Sensitizing Agents for Therapy in Type 2 Diabetes | $ 244,479.24 | |
| Michigan Critical Care Consultants Inc DBA MC3 Inc | Hyperthermia device for cancer treatment | $ 36,179.85 | $ 98,601.27 |
| Michigan Critical Care Consultants Inc DBA MC3 Inc | Catheter Enterogenesis Device Development | $ 40,746.68 | |
| Michigan Critical Care Consultants, Inc. DBA MC3, Inc. | Pediatric blood pump development | $ 93,822.77 | $ 150,656.47 |
| Michigan Critical Care Consultants, Inc. DBA MC3, Inc. | Artificial Lung Development | $ 93,587.07 | $ 150,892.17 |
| Michigan Critical Care Consultants, Inc., DBA MC3, Inc. | Bidirectional Arterial Cannula Development | $ 80,991.20 | $ 163,488.04 |
| Michigan Critical Care Consultants, Inc., DBA MC3, Inc. | Annuloplasty Ring for Heart Valve Disease | $ 17,393.01 | $ 46,276.11 |
| Michigan Critical Care Consultants, Inc., DBA MC3, Inc. | Automatic Perfusion System Development | $ 13,314.69 | $ 70,696.82 |
| Michigan Critical Care Consultants, Inc., DBA MC3, Inc. | Simple Ventricular Assist Device Development | $ 53,422.38 | |
| MICHIGAN TECHNOLOGY & RESEARCH INSTITUTE, LLC | GENETIC CHARACTERIZATION OF FIBROSIS & INFLAMMATORY SUSCEPTIBILITY IN CHRONIC KIDNEY DISEASE | $ 22,191.00 | $ 8,518.71 |
| NanoBio Corporation | Novel Nebulized Therapy for Cystic Fibrosis | $ 244,479.25 | |
| NanoBio Corporation | Novel Topical Therapy for Herpes Labialis | $ 244,479.25 | |
| NanoBio Corporation | Novel Intranasal Vaccine Adjuvant | $ 244,479.25 | |
| NanoBio Corporation | Novel Intranasal 23- Valent Pneumococcal Vaccine | $ 244,479.25 | |
| NanoBio Corporation | Novel Topical Anti-fungal Therapy for Tinea Capitis and Onychomycosis | $ 244,479.25 | |
| NanoVir, L.L.C. | Therapeutic Development of Antiviral Compounds that Target Human Papillomaviruses (HPV) | $ 244,479.24 | |
| Nephrx Corporation | NX001 Treatment of Acute Kidney injury | $ 244,479.24 | |
| NEPHRX Corporation | NS002 Treatment of Oral Mucositis | $ 91,845.50 | $ 152,633.74 |
| NeuroNexus Technologies, Inc. | Deep Brain Stimulation | $ 162,088.50 | $ 47,855.50 |
| Novalung, Inc. | Development of pump for use with artificial lung | $ 226,495.16 | $ 17,984.08 |
| Nustep, Inc | Metabolic Cost of Recumbent Exercise in Overweight Individuals | $ 24,330.00 | |
| Nymirum Inc | Alzheimer's Project | $ 17,248.00 | $ 227,231.25 |
| Nymirum Inc | Hepatitis C Project | $ 9,764.50 | $ 234,714.75 |
| Nymirum, Inc | Myotonic Dystrophy Project | $ 30,283.50 | $ 214,195.75 |
| OtoMedicine Inc | Prevention of Drug Induced Hearing Loss (DIHL) by AuraQuell | $ 98,011.00 | $ 146,468.25 |
| Phrixus Pharmaceuticals, Inc | Heart Failure | $ 168,430.00 | $ 76,049.24 |
| Phrixus Pharmaceuticals, Inc | Duchenne Muscular Dystrophy | $ 168,430.00 | $ 76,049.24 |
| ProNAI Therapeutics, Inc | A Phase 1 Study of PNT2258 in Patients with Advanced Solid Tumors | $ 30,965.00 | $ 213,514.24 |
| QuatRx Pharmaceuticals Company | Ospemifene | $ 244,479.25 | |
| RealBio Technology, Inc. | Biorealistic Tissue models for Drug Discovery and Testing | $ 93,800.00 | $ 150,679.24 |
| RetroSene Therapeutics LLC aka RetroSense Therapeutics LLC | Gene therapy for vision restoration | $ 1,750.00 | $ 161,094.43 |
| Rockwell Medical Technologies, Inc. | Soluble Ferric Pyrophosphate (SFP) indicated for the treatment of iron deficiency anemia | $ 244,479.24 | |
| Rubicon Genomics, Inc | Development of PicoPlex -NGS Kits | $ 85,674.50 | $ 99,166.50 |
| Rubicon Genomics, Inc. | Development of MethylPlex ™ -NGS Kits | $ 80,501.00 | $ 129,187.00 |
| Sonetics Ultrasound, Inc. | Fully-sampled 2D/planar ultrasound transducer technology | $ 185,276.47 | $ 59,202.78 |
| Swift Biosciences Inc | Development of High Sensitivity Genetic Tests for Detection and Assessment of Cancer | $ 244,479.24 | |
| Tangent Medical Technologies | Peripheral intravenous therapeutic delivery device | $ 244,479.25 | |
| TCH Pharmaceuticals, Inc | Imidazoline-based Inhibitors | $ 17,519.50 | $ 26,431.62 |
| Therapeutic System Research Laboratories, Inc. (TSRL) | Anti-Influenza Therapeutic | $ 53,603.56 | $ 43,987.62 |
| Therapeutic Systems Research Laboratories, Inc (TSRL) | Cidofovir, Nucleoside Prodrug for Antiviral Treatment | $ 244,479.25 | |
| Therapeutic Systems Research Laboratories, Inc. (TSRL) | Bile Acid Carrier | $ 85,919.29 | $ 24,184.42 |
| Therapeutic Systems Research Laboratories, Inc. (TSRL) | Inflammatory Bowel Disease Therapeutic | $ 45,127.53 | $ 75,793.37 |
| Tolera Therapeutics, Inc | TOL 101 in Phase 2 short course immune induction therapy for chronic immune disease | $ 244,479.24 | |
| Ultrasound Medical Devices Inc | imaging of cardiovascular mechanical function for assessment diagnosis and therapy guidance | $ 221,258.00 | $ 23,221.25 |
| Velcura Therapeutics, Inc. | VEL-0230 an Orally Available, Disease Modifying Anti-Rheumatic Drug (DMARD) | $ 194,016.10 | |
| Xoran Technologies Inc | Xoran xCAT | $ 244,479.25 | |
| Xoran Technologies, Inc. | Xoran MiniCAT | $ 244,479.25 | |
| zuSyn, Inc. | Development of Novel Taxanes for the Treatment of Cancer | $ 3,280.20 | $ 1,704.58 |
References/Related Topics
Page Last Reviewed or Updated: 2012-10-12
